MINI REVIEW article
COVID-19 Disease and Vitamin D: A Mini-Review
- 1International Research Centre “Biotechnologies of the Third Millennium”, ITMO University, Saint-Petersburg, Russia
- 2Laboratory of Neuroendocrinology, I.P. Pavlov Institute of Physiology, Russian Academy of Sciences, St. Petersburg, Russia
- 3Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russia
- 4Department of Biomedical and Biotechnological Sciences, Biological Tower, School of Medicine, University of Catania, Catania, Italy
- 5UND Life Sciences, Battle Ground, WA, United States
- 6Department of Pharmacology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt
- 7Department of Medical Pharmacology, Medical Faculty, Ataturk University, Erzurum, Turkey
Novel coronavirus disease (COVID-19) pandemic caused by SARS-CoV-2, for which there is no effective treatment except employing prevention strategies, has already instituted significant number of deaths. In this review, we provide a scientific view on the potential role of vitamin D in SARS-CoV-2 virus/COVID-19 disease. Vitamin D is well-known to play a significant role in maintaining the immune health of an individual. Moreover, it induces antimicrobial peptide expression that can decrease viral replication and regulate the levels of pro-inflammatory/anti-inflammatory cytokines. Therefore, supplementation of vitamin D has the potential to reduce the incidence, severity and the risk of death from pneumonia resulting from the cytokine storm of many viral infections including COVID-19. We suggest that supplementation of subjects at high risk of COVID-19 with vitamin D (1.000 to 3.000 IU) to maintain its optimum serum concentrations may be of significant benefit for both in the prevention and treatment of the COVID-19.
The occurrence of respiratory tract infections (RTI) is more common in winter, especially in the northern regions, than in the summer months (Hope-Simpson, 1981). This also applies to the rapidly spreading in the winter period around the world of the infectious Coronavirus disease 2019 (COVID-19) which became a pandemic, since the virus is more easily transmitted at low temperatures (Qu et al., 2020; Sajadi et al., 2020). This rises the possibility that insufficient intake of vitamin D3 may have a role in the development and severity of COVID-19. Thus, in order to curb the current pandemic of COVID-19, it is opined that the administration of an adequate amounts of vitamin D3 may stem the current situation till an effective therapy, chemoprophylaxis, and vaccination is developed.
Deficiency of vitamin D3 in all age groups is a public health problem (Palacios and Gonzalez, 2014) that is well recognized. It is estimated that more than one billion people suffer from vitamin D3 deficiency (Van Schoor and Lips, 2011). Several previous studies suggested that there is an independent association between low plasma concentrations of 25-hydroxyvitamin D3 and susceptibility to acute respiratory infections (Cannell et al., 2006). Vitamin D3 deficiency has been associated with many diseases including but not limited to type 2 diabetes mellitus, heart disease, stroke, autoimmune diseases, asthma and RTIs (Hollick, 2007; Hollick, 2017). The relation between low levels of vitamin D3 and infection with bovine diarrhea virus in calves has been well established (Nonnecke et al., 2014). It is evident that in winter due to the shorter time spent in the sun, the plasma levels of vitamin D3 is likely to be low (Berardi and Newton, 2009; https://www.medlineplus.gov/vitamind.html). This is especially evident in countries such as the United States of America (USA), United Kingdom (UK), Switzerland, Italy, Spain, Iran, France, Turkey, etc. It is rather interesting that COVID-19 pandemic and its high mortality (Pharmacy Times, 2020; https://www.pharmacytimes.com/publications/issue/2010/february2010/otcfocusvitamind-0210) has been reported in these countries. According to the US National Center for Health Statistics, approximately 70% of the population may be deficient in vitamin D3 and surprisingly while the United States is presently the most affected by COVID-19 (Kmiec et al., 2014). This is in line with the current proposal that severe acute respiratory syndrome due to SARS-CoV-2 and its associated high mortality rate may be as a result of vitamin D3 deficiency. Furthermore, vitamin D3 deficiency is known to elevate with increasing age and comorbidities that are associated with lower vitamin D3 levels.
In the current review, we present a scientific rationale on the potential relationship between vitamin D3 content and higher incidence of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) virus infection. Moreover, our review also summarizes the current understanding of the link among vitamin D3, the immune system, and respiratory infections.
Vitamin D and Immune System
Vitamin D is a pluripotent hormone that modulates the innate and adaptive immune responses (Rezaei, 2018). Vitamin D could play a decisive role in the proliferation and immunomodulation of cells, affecting several immune pathways enhancing the protective properties of the mucous membranes of the body and inhibiting excessive inflammation (D’Ambrosio et al., 1998; Khare et al., 2013; Parlak et al., 2015). Immunocytes such as macrophages, B and T lymphocytes, neutrophils and dendritic cells express Vitamin D3 receptors (VDRs) that is enable to the actions of vitamin D (Di Rosa et al., 2011). The active metabolite of vitamin D lead to the activation of VDRs that can form Retinoid X Receptor (RXR) heterodimer that, in turn, influences the proteins of the innate and adaptive immune system (the regulatory T cells, defensins, cytokines, pattern recognition receptors, etc.) (Chun et al., 2014).
The immune system is influenced in various ways by both vitamin D3 and its metabolite 1,25-hydroxy-vitamin D3. 1,25-hydroxy-vitamin D3 rigorously regulates antimicrobial peptides such as defensin and cathelicidin (Adams et al., 2009). Cathelicidin possesses an antimicrobial function against mycobacteria, Gram-positive and Gram-negative bacteria due to its ability to destroy cell membranes. 1,25-hydroxy-vitamin D3 has antiviral effect against adenovirus, herpes simplex virus, enveloped and non-enveloped retroviruses, and fungi (Herr et al., 2007). By damaging cell membranes, these peptides penetrate infected cells and neutralize the action of endotoxins (Agier et al., 2015). For instance, the LL-37, antimicrobe peptide, has antibacterial and antifungal properties by virtue of its ability to disrupt the integrity of the cell membrane and proton gradient (Bals and Wilson, 2003) by vitamin D3 (Howell et al., 2004; Leikina et al., 2005; Steinstraesser et al., 2005; Bergman et al., 2007). In addition, vitamin D3 inhibits the production of pro-inflammatory cytokines and augments that of anti-inflammatory cytokines (Gombart et al., 2020). Thus, vitamin D3 influences the incidence and severity of viral infections by altering the production of pro-inflammatory cytokines. There is reasonable evidence to suggest that vitamin D3 can inhibit the transcription induced by tumor-necrosis-factor-α (TNF-α) in latently infected cells by human immunodeficiency viruses (HIV) (Nunnari et al., 2016). These and other results suggest that vitamin D3 can inhibit the production of inflammatory cytokines and chemokines such as TNF-α, interferon-β (IFN-β), interleukine (IL)-8, IL-6 and Regulated upon Activation, Normal T Cell Expressed and Presumably Secreted (RANTES) (Hansdottir et al., 2010; Khare et al., 2013). Increase in mortality in those with COVID-19 is due to acute respiratory distress syndrome (ARDS) due to unantagonized production of pro-inflammatory cytokines IL-6 and TNF-α. Vitamin D3 has a decisive role in the regulation of the innate and adaptive immune responses implying that adequate intake of vitamin D3 may protect patients with COVID-19 at least, in part by inhibiting the excess production of IL-6 and TNF-α (Daneshkhah et al., 2020). Vitamin D3 can also contribute to the modification of the antiviral response by enhancing the secretion of pro-inflammatory chemokines (C-X-C Motif Chemokine Ligand 8, CXCL8 and C-X-C Motif Chemokine Ligand 10, CXCL10) (Brockman-Schneider et al., 2014). Lytic phase of cytomegalovirus (CMV) replication can be induced by vitamin D3in vitro (Wu and Miller, 2015).
Vitamin D3 promotes immunoglobulin and complement-mediated phagocytosis by stimulating the maturation of monocytes to macrophages. In addition, vitamin D3 maintains self-tolerance by reducing a hyperactive adaptive immune system (Bowie and Unterholzner, 2008). Vitamin D3 reduces the replication of influenza A (Barlow et al., 2011), rotavirus (Zhao et al., 2019) and dengue microbes (Martínez-Moreno et al., 2019). These results imply that excess innate immune response induced by viral and other microbial infections seen in patients with SARS-CoV-2 and associated cytokine storm can be effectively reduced by vitamin D3 (Huang et al., 2020). The immunomodulatory effect of vitamin D3 on viral infections appears to be temporary and at least, this in part could be attributed to its immunomodulatory role in viral infections is rather complex and depends on the nature of the pathogen and the type of immune function that is needed to resolve the disease process (Sacco et al.,2012; Gotlieb et al., 2018).
There is reasonable evidence to suggest that vitamin D3 modulates adaptive immune responses by inhibiting the Th1 cell function that leads to a reduction in the production of TNF-α, IL-2, granulocyte macrophage colony-stimulating factor and IFN-β. 1,25-(OH)2-Vitamin D3 enhances the action of Th2 cells and production of their anti-inflammatory cytokines, IL-4, IL-5, and IL-10 (Hughes and Norton, 2009). In addition, supplementation of vitamin D3 increases the number of regulatory T cells (Treg cells), suppresses IgG production and differentiation of dendritic cells (Kamen and Tangpricha, 2010; Aranow, 2011; Rondanelli et al., 2018). 1,25-(OH)2-Vitamin D3 inhibits the proliferation and activation of T cells and T and B lymphocytes (Martineau et al., 2017). Thus, vitamin D3 suppresses T-cell-mediated inflammation and promote the proliferation of Treg cells that results in an increase in the production of IL-10 that leads to suppression of inappropriate inflammation (Adorini and Penna, 2009; Chun et al., 2014). Vitamin D3 can also increase the expression of glutathione reductase and glutamate–cysteine ligase modifier subunit (Lei et al., 2017) that may lead to a decrease in oxidative stress. These results led to the proposal that (Biancatelli et al., 2019; Mousavi et al., 2019; Wimalawansa, 2020) vitamin D3 may be of benefit to combat SARS-CoV-2 infection (Grant et al., 2020a).
Vitamin D deficiency is common in patients with HIV (Herr et al., 2007). The antiviral action of vitamin D3 can also be attributed to its ability to increase the production of cathelicidin and defensins (Herr et al., 2007; Hughes and Norton, 2009; Beard et al., 2011). Furthermore, 1,25-dihydroxy-cholecalciferol is known to regulate more than 200 genes including those responsible for cell proliferation, differentiation, and apoptosis (Umar and Sastry, 2018) including those involved in immune homeostasis (Van Herwegen et al., 2017). Recent meta-analysis of randomized controlled trials (RCTs) showed that vitamin D deficiency increases the overall mortality (Bjelakovic et al., 2014; Keum et al., 2019; Manson et al., 2019; Scragg, 2020). All above-mentioned effects of Vitamin D3 are presented in Table 1.
Relevance of Vitamin D Regarding to Respiratory Tract Infections and Influenza
There is a provided evidence given by many reviewed studies to support the hypothesis that higher serum level of vitamin D3 is associated with a low risk of microbial infections and deaths from RTIs caused by pneumonia and influenza. In addition, SARS-CoV-2 infection and decrease the severity and mortality may be avoided by a normal serum vitamin D3 levels (Wimalawansa, 2020). Unfortunately, there are no standard recommendations regarding the dose and the desired optimal concentration of vitamin D3 required to protect people from RTI during the winter season.
Epidemiological studies revealed that vitamin D3 plays a critical role in viral RTIs and associated acute lung injury (Hansdottir and Monick, 2011). In a recent meta-analysis, it has been shown that a daily or weekly vitamin D3 dose between 20 and 50 μg resulted in a significant reduction of RTIs (Martineau et al., 2017). A high-dose, isolated, or added bolus of (2.5 mg once or monthly) did not reduce the risk. One study supplemented for one-year high risk individual for ARDS with a 100 μg/daily (Bergman et al., 2012). The overall infection score was significantly reduced in the treated groups, and those with vitamin D3 deficiency showed the greatest benefit of the supplementation.
In addition, it is observed that the degree of protection generally increases when the concentration of vitamin D3 reaches its optimal range of 40 to 60 ng/ml. To reach this level, an individual must take between 2,000 and 5,000 IU/day of vitamin D3 (Heaney et al., 2003). Calcitriol protects against acute lung injury by modulating the expression of the renin–angiotensin system including angiotensin-converting enzyme 2 (ACE2) in lung tissue (Xu et al., 2017). There seems to be a direct relationship between plasma 25-(OH)-Vitamin D3 concentrations and severity of COVID-19 (Huang et al., 2020; Wang et al., 2020; Zhou et al., 2020). It is noteworthy that the expression of the DPP-4/CD26 receptor is significantly reduced as a result of vitamin D3 deficiency (Komolmit et al., 2017). Furthermore, adequate provision of vitamin D3 seems to attenuate immunological events that may lead to prolonged interferon-gamma response (Zdrenghea et al., 2017), and persistent interleukin six elevation that are negative prognostic value indicators in those with severe COVID-19 (Miroliaee et al., 2018).
VDRs are very widely distributed in respiratory epithelial cells and immune cells (B cells, T cells, macrophages and monocytes). VDRs are in the epithelium of the bronchi and immune cells (Pfeffer and Hawrylowicz, 2012). The enzyme, 1a-hydroxylase (CYP27B1), required for vitamin D activation, is induced by diverse stimuli, including cytokines and toll-like receptor ligands in the respiratory tract. Nevertheless, adequate serum levels of 25-(OH)-vitamin D3 is required to increase levels of 1,25-(OH)2-vitamin D3 and to improve the immune response to respiratory virus infections (Greiller and Martineau, 2015). The development of ARDS shows typical changes in membrane permeability of the alveolar capillary, progressive edema, severe arterial hypoxemia and pulmonary hypertension (Matthay et al., 2012). In animal studies, vitamin D3 significantly attenuated lung damage caused by lipopolysaccharides (LPS) (Xu et al., 2017). This is noteworthy since LPS increase the pulmonary expression of renin and angiotensin 2 (Ang 2) that promotes inflammation. Vitamin D3 reduces the increased renin and Ang 2 expression and thus significantly lowers lung injury. It has been suggested that vitamin D3 promotes ACE2/Ang 1–7 activity. This is supported by the observation that calcitriol treatment significantly increased the expression of VDR mRNA and ACE2 mRNA that leads to a reduction in angiotensin II, ACE2 expression resulting in suppression of inflammation (Yang et al., 2016). VDRs are not only a negative regulator of renin, but also of NF-kB (Li et al., 2004), leading to an increase in Ang 2 formation, which promotes pro-inflammation (Jurewicz et al., 2007).
Down-regulation of ACE2 expression by SARS-CoV infection is associated with acute lung damage (edema, increased vascular permeability, reduced lung function) and associated RAS dysregulation leads to increased inflammation and vascular permeability as seen in COVID-19 (Imai et al., 2005). It was reported that COVID-19 is associated with release of pro-vitamin D3 enhances the cellular immunity and reduces the cytokine storm induced by the innate immune system. Vitamin D3 can reduce the production of pro-inflammatory cytokines such as TNF-α and IF-γ (Tjabringa et al., 2005; Baeke et al., 2010; Laaki, 2012). Several studies showed that adequate intake and plasma levels of vitamin D3 reduces the risk of viral infections through their action on immunocytes (Carnell et al., 2006; Baeke et al., 2010; Schwalfenberg, 2011; Lang and Samaras, 2012). Hence, it is suggested that vitamin D3 may have a significant role in COVID-19 due to its action on T cells (Zhang et al., 2015).
Type-II pneumocytes which are the primary target of coronaviruses, express high levels of ACE2 receptor (Bombardini and Picano, 2020). Metabolites of 25-(OH)-vitamin D3 have been reported to stimulate surfactant synthesis in alveolar type-II cells (Rehan et al., 2002). Human fetal and adult alveolar type-II cells supplemented with 1,25-dihydroxy-vitamin D3 show increased levels of VDRs and expression of surfactant associated protein B, a lipid-associated protein of the pulmonary surfactant, indicating the potential of vitamin D3 to reduce surface tension in COVID-19 (Phokela et al., 2005).Comorbid conditions such as diabetes mellitus, hypertension and chronic obstructive pulmonary disease are commonly associated with low plasma vitamin D3 levels (Malinovschi et al., 2014; Kim et al., 2015; Grant et al., 2020a). Hence, it is reasonable to propose that COVID-19 may be associated with low plasma vitamin D3 levels. Hence, it is suggested that vitamin D3 supplementation may be of significant benefit in COVID-19. Grant, in the latest report, suggest that vitamin D level checking will be conducted only in as elected category of patients that involves pregnant mothers, obese and elderly people and others suffering from certain comorbid conditions (Grant et al., 2020b). Multiple factors such as an ability of the assimilation by the gastrointestinal tract, body weight, genetic factors and the baseline 25-(OH)-vitamin D3 concentration, control the increase in vitamin D concentrations with respect to oral vitamin D3 supplementation. Given the degree of vitamin D3 deficiency, taking 5,000 IU of vitamin per day, it could be essential to elevate 25-(OH)-vitamin D3 levels to 40 ng/ml by (Veugelers et al., 2015).
A recent article indicates that vitamin D3 value >20 ng/ml is required and this advice is adopted by several countries (Amrein et al., 2020). Another research suggests a higher dose for RTIs, indicating rates >30 ng/ml of vitamin D3 as effective in decreasing cancer incidence, unfavorable pregnancy and birth outcomes and type 2 diabetes mellitus (Grant et al., 2020b). From another analysis it is suggested that optimal vitamin D3 standard should be 40–60 ng/ml for prevention of breast and colorectal cancer (Garland et al., 2009).
The U.S. Institute of Medicine noted that no research observed negative consequences of supplementation of vitamin D3 of less than 10,000 IU/daily, but set the upper consumption limit at 4,000 IU/daily, partially owing to retrospective tests that found U-shaped 25-(OH)-vitamin D3 concentration/health outcome relationships. However, further findings indicate that most observations of J- or U-shaps relationships came from observational studies that did not test serum 25-(OH)-vitamin D3 concentrations, and that the likely explanation for these relationships was the presence of some participants who started taking vitamin D3 complementation shortly before registration (Grant et al., 2016). Particularly in winter, supplementation with vitamin D3 is required for many individuals to reach concentrations of 25-(OH)-vitamin D3 above 30 ng/ml (Pludowski et al., 2018). However, vitamin D3 fortification of basic foods such as dairy and flour products may increase serum 25(OH)D concentrations by a few ng/ml among those members of different populations with the lowest concentrations (Pilz et al., 2018; Grant and Boucher 2019). This will contribute to a decreased risk of ARTIs for persons with a severe vitamin D3 deficiency (Camargo et al., 2012; Martineau et al., 2017). However, regular or weekly treatment of vitamin D3 is advised for greater benefits (Martineau et al., 2017), as is the annual evaluation of serum 25-(OH)-vitamin D3 levels for health risks individuals (Grant et al., 2020b).
Table 2 describes the findings from meta-analyses that vitamin D3 is protective against acute RTI, particularly in patients with vitamin D3 deficiency.
Hypothesis of the Correlation on Vitamin D3 Levels and Coronavirus Disease-19 Cases/Severity
Still there is a lack of a cohort studies and clinical trials in determining the role of vitamin D3 in the prevention of COVID-19 infections and/or severity. Some retrospective studies have demonstrated the relationships between vitamin D3 levels and COVID-19 cases and severity (Table 3).
TABLE 3. The outcomes in recent studies about the correlation of vitamin D3 concentrations with COVID-19 infections.
For example, a preliminary information study from Philippines on 212 reported COVID-19 patients, found that the severity of the infection is a highly correlated to the vitamin D3 levels (Alipio, 2020). Authors have found that 85.5% of patients with an adequate status of vitamin D3 (>30 ng/ml) showed a moderate disease, while a 72.8% of patients with vitamin D3 deficiency (<20 ng/ml) had the serious disease symptoms (Alipio, 2020). The correlation between vitamin D3 and COVID-19 have extensively investigated in a group of 178 Indonesians (Raharusun et al., 2020). According to this study, the patients with vitamin D3 levels in the categories, 20–30 and <20 ng/ml, were 12.55 times and 19.12 times more likely to die from COVID-19, respectively, as compared with COVID-19 patients with sufficient levels of vitamin D3. The main conclusion is that, even after controlling for age, sex and comorbidities, deaths were 10.12 times more likely in patients with vitamin D3 deficiency than in patients with normal vitamin D3 levels (Raharusun et al., 2020). A limited cohort observational study with 43 cases in Singapore have found that a treatment of COVID-19 patients with an oral doses of vitamin D3 (1.000 IU), Mg (150 mg), and vitamin B12 (500 μg) significantly reduced the application of the subsequent oxygen therapy compared to controls (3/17 vs. 16/26, p = 0.006) (Tan et al., 2020). Furthermore, such drugs combination have protected against the clinical deterioration (p = 0.041) even after adjustment of confounders (age, sex and comorbidity) (Tan et al., 2020). Severe COVID-19 patients and patients with pre-existing medical conditions were reported to have low levels of vitamin D3 (Glicio et al., 2020; Lau et al., 2020). A retrospective observational study with 186 positive cases and 2717 negative controls in Belgium have demonstrated a low median for vitamin D3 in the COVID-19 patients compared to the control subjects (p = 0.0016) (De Smet et al., 2020). A retrospective cohort study with 780 cases in Indonesia showed that below-normal vitamin D3 levels and the pre-existing medical conditions in the older and male cases have higher odds of death. Moreover, the vitamin D3 status has a strong relationship with COVID-19 mortality if it adjusted for age, sex and comorbidities (Raharusun et al., 2020). The similar retrospective study in the USA with many cases have showed that the reduced risks for both COVID-19 cases and the mortality are possibly associated with the sunlight and vitamin D3, as well with the latitude as an indicator (Li et al., 2020).
In a new systematic review and meta-analysis with an ecological approach, they found a high percentage of COVID-19 patients who suffer from vitamin D3 deficiency or insufficiency. Much more important its ecological investigation resulted in the substantial direct and reverse correlations between the recovery and mortality rates in COVID-19 patients with vitamin D3 deficiency at the different countries. A small reverse correlation between vitamin D3 status and the mortality rate have found globally. The populations with a lower levels of vitamin D3 might be more susceptible to the novel coronavirus infection (Ghasemian et al., 2020). Recently, a cohort study of 489 patients who had a vitamin D3 levels detected in the year before COVID-19 testing was 1.77 times greater for patients with vitamin D3 deficiency compared to the patients with a normal vitamin D3 status. These findings appear to support a role of vitamin D3 status for the COVID-19 risk (Meltzer et al., 2020).
The hypothesis that supplementation with vitamin D3 may reduce the risk of influenza and COVID-19 disease, as well the death should be examined in the trials to evaluate the correct doses, the serum 25-(OH)-vitamin D3 concentrations and the existence of any health concerns. There are a good model from Atlanta and Georgia in which have done the RCT on vitamin D3 supplementation for the ventilated ICU patients (Han et al., 2016).
There is a recommendation to take a vitamin D3 at 10,000 IU/day as an acceptable dose to raise circulatory concentration of vitamin D3 to the optimum range of 40–60 ng/ml; after 1 month this dose should be lowered to 5,000 IU/day to the sustain serum rate (Ekwaru et al., 2014; Shirvani et al., 2019). A recent study have suggested a loading doses of 200,000–300,000 IU of vitamin D3 to reach the optimum serum range, thereby the reducing of the risk/severity for COVID-19 (Wimalawansa, 2020).
The observation that normal vitamin D3 status is important for the immune system as well as for the regulation of SAR should lead to a correction of vitamin D3 status if a deficiency has been detected. There is no experience with the use of vitamin D3 in COVID-19. In addition, it should be noted that a very high doses of the upper limit of 4,000 IU (100 μg) per day of vitamin D3 still have the risks and may be dangerous. Since such doses might result in to the improvements in the VDR competency and could have an inhibitory impact on the immune function (Mangin et al., 2014).
It is evident from the preceding discussion that vitamin D3 may be of benefit in COVID-19. Since the higher plasma concentrations of vitamin D3 is better for the protection from various viral and respiratory infections, it is reasonable to suggest that regular supplementation of vitamin D3 to those who are at high risk of developing various viral respiratory infections including COVID-19 need to considered seriously. To verify this proposal, double-blind placebo-controlled trials and large-scale intervention and prevention studies using vitamin D3 are needed. If this proposal is true it leads to the development of a simple, easily implementable method of preventing the incidence of COVID-19 and reducing its serious complications by simple oral supplementation of vitamin D3. Furthermore, vitamin D3 has several other benefits in the form of preventing rickets, improving general health, and reducing mortality due to its deficiency (though the exact cause for this association is not clear) add strength to the concept that its supplementation is warranted.
MB, VI, RM, DB interpreted the data from the literature. MB, VI, RM, JF, DB wrote the original draft. MB, VI, RM, JF, FD, LG, UD, AE-A reviewed, edited and drafted the manuscript, and approved the final version.
Conflict of Interest
UD was employed by the company UND Life Sciences LLC.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.
Adams, J. S., Ren, S., Liu, P. T., Chin, R. F., Lagi Shetty, V., Gombart, A. F., et al. (2009). Vitamin d-directed rheostatic regulation of monocyte antibacterial responses. J. Immunol. 182, 4289–4295. doi:10.4049/jimmunol.0803736
Alipio, M. M. (2020). Letter-preprint vitamin D supplementation could possibly improve clinical outcomes of patients infected with coronavirus-2019 (Covid-2019). Available at: https://www.ssrn.com/abstract=3571484 (Accessed 09 May, 2020).
Amrein, K., Scherkl, M., Hoffmann, M., Neuwersch-Sommeregger, S., Köstenberger, M., Berisha, A. T., et al. (2020). Vitamin D deficiency 2.0: an update on the current status worldwide. Eur. J. Clin. Nutr. 20, 1–16. doi:10.1038/s41430-020-0558-y
Barlow, P., Svoboda, P., Mackellar, A., Nash, A., York, I., Pohl, J., et al. (2011). Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS One. 6, e25333. doi:10.1371/journal.pone.0025333
Bergman, P., Walter-Jallow, L., Broliden, K., Agerberth, B., and Soderlund, J. (2007). The antimicrobial peptide LL-37 inhibits HIV-1 replication. Curr. HIV Res. 5:410–415. doi:10.2174/157016207781023947
Bergman, P., Lindh, Å., Björkhem-Bergman, L., and Lindh, J. (2013). Vitamin D and respiratory tract infections: a systematic review and meta-analysis of randomized controlled trials. PloS One 8, e65835. doi:10.1371/journal.pone.0065835
Bergman, P., Norlin, A. C., Hansen, S., Rekha, R. S., Agerberth, B., Bjorkhem-Bergman, L., et al. (2012). Vitamin D3 supplementation in patients with frequent respiratory tract infections: a randomized and double-blind intervention study. BMJ Open 2, e001663. doi:10.1136/bmjopen-2012-001663
Bjelakovic, G., Gluud, L. L., Nikolova, D., Whitfield, K., Wetterslev, J., Simonetti, R. G., et al. (2014). Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst. Rev. 1:CD007470. doi:10.1002/14651858.CD007470.pub3
Bombardini, T., and Picano, E. (2020). Angiotensin converting enzyme 2 as the molecular bridge between epidemiologic and clinical features of COVID-19. Can. J. Cardiol. 36 (5), 784.e1–784.e2. doi:10.1016/j.cjca.2020.03.026
Brockman-Schneider, R. A., Pickles, R. J., and Gern, J. E. (2014). Effects of vitamin D on airway epithelial cell morphology and rhinovirus replication. PLoS One 9 (1), e86755. doi:10.1371/journal.pone.0086755
Camargo, C. A., Ganmaa, D., Frazier, A. L., Kirchberg, F. F., Stuart, J. J., Kleinman, K., et al. (2012). Randomized trial of vitamin D supplementation and risk of acute respiratory infection in Mongolia. Pediatrics. 130, e561–e567. doi:10.1542/peds.2011-3029
Charan, J., Goyal, J., Saxena, D., and Yadav, P. (2012). Vitamin D for prevention of respiratory tract infections: a systematic review and meta-analysis. J. Pharmacol. Pharmacother. 3, 300–303. doi:10.4103/0976-500X.103685
Chen, S., Sims, G. P., Chen, X. X., Gu, Y. Y., Chen, S., and Lipsky, P. E. (2007). Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J. Immunol. 179, 1634–1647. doi:10.4049/jimmunol.179.3.1634
Chun, R. F., Liu, P. T., Modlin, R. L., Adams, J. S., and Hewison, M. (2014). Impact of vitamin D on immune function: lessons learned from genome-wide analysis. Front. Physiol. 5, 151. doi:10.3389/fphys.2014.00151
Daneshkhah, A., Agrawal, V., Eshein, A., Subramanian, H., Roy, H. K., and Backman, V. (2020). The possible role of vitamin D in suppressing cytokine storm and associated mortality in COVID-19 patients. Med Rxiv Preprint. doi:10.1101/2020.04.08.20058578
Daniel, C., Sartory, N. A., Zahn, N., Radeke, H. H., and Stein, J. M. (2008). Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J. Pharmacol. Exp. Therapeut. 324, 23–33. doi:10.1124/jpet.107.127209
Darling, A. L., Ahmadi, K. R., Ward, K. A., Harvey, N. C., Alves, A. C., Dunn-Waters, D. K., et al. (2020). Vitamin D status, body mass index, ethnicity and COVID-19: Initial analysis of the first-reported UK Biobank COVID-19 positive cases (n 580) compared with negative controls (n 723). MedRxiv. doi:10.1101/2020.04.29.20084277
De Smet, D., De Smet, K., Herroelen, P., Gryspeerdt, S., and Martens, G. A. (2020). Vitamin D deficiency as risk factor for severe COVID-19: a convergence of two pandemics. Med Rxiv Preprint.doi:10.1101/2020.05.01.20079376
D’Ambrosio, D., Cippitelli, M., Cocciolo, M., Mazzeo, D., Di Lucia, P., Lang, R., et al. (1998). Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J. Clin. Invest. 101, 252–262. doi:10.1172/JCI1050
Ekwaru, J., Zwicker, J., Holick, M., Giovannucci, E., and Veugelers, P. (2014). The importance of body weight for the dose response relationship of oral Vitamin D supplementation and serum 25-hydroxyvitamin D in healthy volunteers. PLoS One 9, e111265. doi:10.1371/journal.pone.0111265
Fritsche, J., Mondal, K., Ehrnsperger, A., Andreesen, R., and Kreutz, M. (2003). Regulation of 25-hydroxyvitamin D3-1 alpha-hydroxylase and production of 1 alpha,25-dihydroxyvitamin D3 by human dendritic cells. Blood 102, 3314–3316. doi:10.1182/blood-2002-11-3521
Ghasemian, R., Shamshirian, A., Heydari, K., Malekan, M., Alizadeh-Navaei, R., Ebrahimzadeh, M. A., et al. (2020). The role of vitamin D in the age of COVID-19: a systematic review and meta-analysis along with an ecological approach. Med Rxiv Preprint. doi:10.1101/2020.06.05.20123554
Glicio, E. J., Neelam, S., Rashi, R., and Ramya, D. (2020). Vitamin D level of mild and severe elderly cases of COVID-19: a preliminary report. Available at: http://vitaminad.nositio.eu/SSRN-id3593258.pdf
Godbole, H., Jang, J., Hong, K., Park, J., and Choi, E. (2015). Relationship between serum Vitamin D concentrations and clinical outcome of community-acquired pneumonia. Int. J. Tubercul. Lung Dis. 19, 729–734. doi:10.5588/ijtld.14.0696
Gotlieb, N., Tachlytski, I., Lapidot, Y., Sultan, M., Safran, M., and BenAri, Z. (2018). Hepatitis B virus downregulates vitamin D receptor levels in hepatoma cell lines, thereby preventing vitamin Ddependent inhibition of viral transcription and production. Mol. Med. 24, 53. doi:10.1186/s10020-018-0055-0
Grant, W. B., and Boucher, B. J. (2019). A review of the potential benefits of increasing vitamin D status in Mongolian adults through food fortification and vitamin D supplementation. Nutrients 11, E2452. doi:10.3390/nu11102452
Grant, W. B., Karras, S. N., Bischoff-Ferrari, H. A., Annweiler, C., Boucher, B. J., et al. (2016). Do studies reporting 'U'-shaped serum 25-hydroxyvitamin D-health outcome relationships reflect adverse effects? Dermatoendocrinol 8, e1187349. doi:10.1080/19381980.2016.1187349
Grant, W. B., Anouti, F., and Moukayed, M. (2020b). Targeted 25 hydroxyvitamin D concentration measurement and vitamin D3 supplementation can have important patient and public health benefits. Eur. J. Clin. Nutr. 74, 366–376. doi:10.1038/s41430-020-0564-0
Grant, W., Lahore, H., McDonnell, S., Baggerly, C., French, C., Aliano, J., et al. (2020a). Evidence that Vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients 12, 988. doi:10.3390/nu12040988
Han, J. E., Jones, J. L., Tangpricha, V., Brown, M. A., Brown, L. A. S., Hao, L., et al. (2016). High dose vitamin D administration in ventilated intensive care unit patients: a pilot double blind randomized controlled trial. J. Clin. Transl. Endocrinol. 4, 59–65. doi:10.1016/j.jcte.2016.04.004
Hansdottir, S., Monick, M. M., Lovan, N., Powers, L., Gerke, A., and Hunninghake, G. W. (2010). Vitamin D decreases respiratory syncytial virus induction of NF-kappaB-linked chemokines and cytokines in airway epithelium while maintaining the antiviral state. J. Immunol. 184, 965. doi:10.4049/jimmunol.0902840
Hastie, C. E., Mackay, D. F., Ho, F., Celis-Morales, C. A., Katikireddi, S. V., Niedzwiedz, C. L., et al. (2020). Vitamin D concentrations and COVID-19 infection in UK Biobank. Diabetes Metabol. Syndr. 14 (4), 561–565. doi:10.1016/j.dsx.2020.04.050
Heaney, R., Davies, K., Chen, T., Holick, M., and Barger-Lux, M. (2003). Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am. J. Clin. Nutr. 77, 204–210. doi:10.1093/ajcn/77.1.204
Howell, M., Jones, J., Kisich, K., Streib, J., Gallo, R., and Leung, D. (2004). Selective killing of Vaccinia virus by LL-37: implications for eczema vaccinatum. J. Immunol. 172, 1763–1767. doi:10.4049/jimmunol.172.3.1763
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506. doi:10.1016/S0140-6736(20)30183-5
Ilie, P. C., Stefanescu, S., and Smith, L. (2020). The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clin. Exp. Res. 32 (7), 1195–1198. doi:10.1007/s40520-020-01570-8
Jurewicz, M., McDermott, D. H., Sechler, J. M., Tinckam, K., Takakura, A., Carpenter, C. B., et al. (2007). Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation, J. Am. Soc. Nephrol. 18, 1093–1102. doi:10.1681/ASN.2006070707
Keum, N., Lee, D. H., Greenwood, D. C., Manson, J. E., and Giovannucci, E. (2019). Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials. Ann. Oncol. 30, 733–743. doi:10.1093/annonc/mdz059
Khare, D., Godbole, N. M., Pawar, S. D., Mohan, V., Pandey, G., Gupta, S., et al. (2013). Calcitriol [1, 25[OH]2 D3] pre- and post-treatment suppresses inflammatory response to influenza A (H1N1) infection in human lung A549 epithelial cells. Eur. J. Nutr. 52, 1405–1415. doi:10.1007/s00394-012-0449-7
Kmiec, P., Zmijewski, M., Waszak, P., Sworczak, K., and Lizakowska-Kmieć, M. (2014). Vitamin D deficiency during winter months among an adult, predominantly urban, population in Northern Poland. Endokrynol. Pol. 65, 105–113. doi:10.5603/EP.2014.0015
Komolmit, P., Charoensuk, K., Thanapirom, K., Suksawatamnuay, S., Thaimai, P., Chirathaworn, C., et al. (2017). Correction of vitamin D deficiency facilitated suppression of IP-10 and DPP IV levels in patients with chronic hepatitis C: a randomised double-blinded, placebo-control trial. PLoS One 12, e0174608. doi:10.1371/journal.pone.0174608
Lei, G., Zhang, C., Cheng, B., and Lee, C. (2017). Mechanisms of action of Vitamin D as supplemental therapy for pneumocystis pneumonia. Antimicrob. Agents Chemother. 61, e01226. doi:10.1128/AAC.01226-17
Leikina, E., Delanoe-Ayari, H., Melikov, K., Cho, M. S., Chen, A., Waring, A. J., et al. (2005). Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. Nat. Immunol. 6, 995–1001. doi:10.1038/ni1248
Lemire, J. M., Archer, D. C., Beck, L., and Spiegelberg, H. L. (1995). Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J. Nutr. 125 (6 Suppl. l), 1704S–1708S. doi:10.1093/jn/125.suppl_6.1704S
Li, Y. C., Qiao, G., Uskokovic, M., Xiang, W., Zheng, W., and Kong, J. (2004). Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J. Steroid Biochem. Mol. Biol. 89-90, 387–392. doi:10.1016/j.jsbmb.2004.03.004
Li, Y., Li, Q., Zhang, N., and Liu, Z. (2020). Sunlight and vitamin D in the prevention of coronavirus disease (COVID-19) infection and mortality in the United States. Res Square. doi:10.21203/rs.3.rs-32499/v1
Liu, P. T., Stenger, S., Tang, D. H., and Modlin, R. L. (2007). Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J. Immunol. 179, 2060–2063. doi:10.4049/jimmunol.179.4.2060
Malinovschi, A., Masoero, M., Bellocchia, M., Ciuffreda, A., Solidoro, P., Mattei, A., et al. (2014). Severe Vitamin D deficiency is associated with frequent exacerbations and hospitalization in COPD patients. Respir. Res. 15, 131–135. doi:10.1186/s12931-014-0131-0
Manson, J. E., Cook, N. R., Lee, I. M., Christen, W., Bassuk, S. S., Mora, S., et al. (2019). Vitamin D supplements and prevention of cancer and cardiovascular disease. N. Engl. J. Med. 380, 33–44. doi:10.1056/NEJMoa1809944
Martineau, A. R., Jolliffe, D. A., Hooper, R. L., Greenberg, L., Aloia, J. F., Bergman, P., et al. (2017). Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ 356, i6583. doi:10.1136/bmj.i6583
Martínez-Moreno, J., Hernandez, J., and Urcuqui-Inchima, S. (2019). Effect of high doses of Vitamin D supplementation on dengue virus replication, toll-like receptor expression, and cytokine profiles on dendritic cells. Mol. Cell. Biochem. 464, 169–180. doi:10.1007/s11010-019-03658-w
Meltzer, D. O., Best, T. J., Zhang, H., Vokes, T., Arora, V., and Solway, J. (2020). Association of vitamin D status and other clinical characteristics with COVID-19 test results. JAMA Netw Open 3 (9), e2019722. doi:10.1001/jamanetworkopen.2020.19722
Miroliaee, A. E., Salamzadeh, J., Shokouhi, S., and Sahraei, Z. (2018). The study of vitamin D administration effect on CRP and Interleukin-6 as prognostic biomarkers of ventilator associated pneumonia. J. Crit. Care 44, 300–305. doi:10.1016/j.jcrc.2017.08.040
Nonnecke, B. J., McGill, J. L., Ridpath, J. F., Sacco, R. E., Lippolis, J. D., and Reinhardt, T. A. (2014). Acute phase response elicited by experimental bovine diarrhea virus (BVDV) infection is associated with decreased vitamin D and E status of vitamin-replete preruminant calves. J. Dairy Sci. 97, 5566. doi:10.3168/jds.2014-8293
Nunnari, G., Fagone, P., Lazzara, F., Longo, A., Cambria, D., Di Stefano, G., et al. (2016). Vitamin D3 inhibits TNF alpha induced latent HIV reactivation in J‐LAT cells. Mol. Cell. Biochem. 418, 49–57. doi:10.1007/s11010-016-2732-z
Parlak, E., Ertürk, A., Çağ, Y., Sebin, E., and Gümüşdere, M. (2015). The effect of inflammatory cytokines and the level of vitamin D on prognosis in Crimean-Congo hemorrhagic fever. Int. J. Clin. Exp. Med. 8, 18302–18310
Penna, G., and Adorini, L. (2000). 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol. 164, 2405–2411. doi:10.4049/jimmunol.164.5.2405
Phokela, S. S., Peleg, S., Moya, F. R., and Alcorn, J. L. (2005). Regulation of human pulmonary surfactant protein gene expression by 1alpha,25-dihydroxyvitamin D3. Am. J. Physiol. Lung Cell Mol. Physiol. 289, L617–L626. doi:10.1152/ajplung.00129.2004
Piemonti, L., Monti, P., Sironi, M., Fraticelli, P., Leone, B. E., Dal Cin, E., et al. (2000). Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J. Immunol. 164, 4443–4451. doi:10.4049/jimmunol.164.9.4443
Pilz, S., Marz, W., Cashman, K. D., Kiely, M. E., Whiting, S. J., Holick, M. F., et al. (2018). Rationale and plan for vitamin D food fortification: a review and guidance paper. Front. Endocrinol., 9. 373. doi:10.3389/fendo.2018.00373
Pludowski, P., Holick, M. F., Grant, W. B., Konstantynowicz, J., Mascarenhas, M. R., Haq, A., et al. (2018). Vitamin D supplementation guidelines. J. Steroid Biochem. Mol. Biol. 175, 125–135. doi:10.1016/j.jsbmb.2017.01.021
Qu, G., Li, X., and Jiang, G. (2020). An imperative need for research on the role of environmental factors in transmission of novel coronavirus (COVID-19). Environ. Sci. Technol. 12, 22–30. doi:10.1021/acs.est.0c01102
Raharusun, P., Priambada, S., Budiarti, C., Agung, E., and Budi, C. (2020). “Patterns of COVID-19 mortality and vitamin D: an Indonesian study,” in SSRN electron. Available from:https://www.papers.ssrn.com/sol3/papers.cfm?abstract_id=3585561
Rehan, V. K., Torday, J. S., Peleg, S., Gennaro, L., Vouros, P., Padbury, J., et al. (2002). 1Alpha,25-dihydroxy-3-epi-vitamin D3, a natural metabolite of 1alpha,25-dihydroxy vitamin D3: production and biological activity studies in pulmonary alveolar type II cells. Mol. Genet. Metab. 76, 46–56. doi:10.1016/s1096-7192(02)00022-7
Rondanelli, M., Miccono, A., Lamburghini, S., Avanzato, I., Riva, A., Allegrini, P., et al. (2018). Self-care for common colds: the pivotal role of vitamin D, vitamin C, zinc, and echinacea in three main immune interactive clusters (physical barriers, innate and adaptive immunity) involved during an episode of common colds—practical advice on dosages and on the time to take these nutrients/botanicals in order to prevent or treat or treat common colds. Evid. Based Compl. Alt. Med. 2018, 1–36. doi:10.1155/2018/5813095
Sacco, R. E., Nonnecke, B. J., Palmer, M. V., Waters, W. R., Lippolis, J. D., and Reinhardt, T. A. (2012). Differential expression of cytokines in response to respiratory syncytial virus infection of calves with high or low circulating 25‐hydroxyvitamin D3. PLoS One 7, e33074. doi:10.1371/journal.pone.0033074
Sajadi, M. M., Habibzadeh, P., Vintzileos, A., Shokouhi, S., Miralles-Wilhelm, F., and Amoroso, A. (2020). Temperature, humidity and latitude analysis to predict potential spread and seasonality for COVID-19. Available at: https://ssrn.com/abstract=3550308
Schwalfenberg, G. A. (2011). A review of critical role of Vit. D functioning of immune system and the clinical importance of Vit. D deficiency. Mol. Nutr. Food Res. 55, 96–108. doi:10.1002/mnfr.201000174
Shirvani, A., Kalajian, T., Song, A., and Holick, M. (2019) Disassociation of Vitamin D’s calcemic activity and non-calcemic genomic activity and individual responsiveness: a randomized controlled double-blind clinical trial. Sci. Rep. 9, 17685. doi:10.1038/s41598-019-53864-1
Sigmundsdottir, H., Pan, J., Debes, G. F., Alt, C., Habtezion, A., Soler, D., et al. (2007). DCs metabolize sunlight-induced vitamin D3 to ‘program’ T cell attraction to the epidermal chemokine CCL27. Nat. Immunol. 8, 285–293. doi:10.1038/ni1433
Steinstraesser, L., Tippler, B., Mertens, J., Lamme, E., Homann, H., Lehnhardt, M., et al. (2005). Inhibition of early steps in the lentiviral replication cycle by cathelicidin host defense peptides. Retrovirol 2, 2. doi:10.1186/1742-4690-2-2
Tan, C. W., Ho, L. P., Kalimuddin, S., Cherng, B. P. Z., Teh, Y. E., Thien, S. Y., et al. (2020). A cohort study to evaluate the effect of combination Vitamin D. Magnesium and Vitamin B12 (DMB) on progression to severe outcome in older COVID-19 patients. Med Rxiv Preprint. doi:10.1101/2020.06.01.20112334
The Pharmacy Times (2020). The important role of vitamin D. Pharmacy Times Available at: https://www.pharmacytimes.com/publications/issue/2010/february2010/otcfocusvitamind-0210
Tjabringa, G. S., Rabe, K. F., and Hiemstra, P. S. (2005). The human cathelicidin LL-37: a multifunctional peptide involved in infection and inflammation in the lung. Pulm. Pharmacol. Ther. 18, 321–327. doi:10.1016/j.pupt.2005.01.001
Veugelers, P. J., Pham, T. M., and Ekwaru, J. P. (2015) Optimal vitamin D supplementation doses that minimize the risk for both low high serum 25-hydroxy vitamin D concentration in general population. Nutrients 7, 10189–10208. doi:10.3390/nu7125527
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., et al. (2020). Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, China. J. Am. Med. Assoc. 323, 1061–1069. doi:10.1001/jama.2020.1585
Wimalawansa, S. J. (2020). Global epidemic of coronavirus-COVID-19: what we can do to minimize risks. Eur. J. Biomed. Pharm. Sci. 7, 432–438. Available at: https://www.ejbps.com/ejbps/abstract_id/6656
Wu, S.-E., and Miller, W. E. (2015). The human cytomegalovirus lytic cycle is induced by 1,25‐dihydroxyvitamin D3 in peripheral blood monocytes and in the THP1 monocytic cell line. Virol 483, 8395. doi:10.1016/j.virol.2015.04.004
Xu, J., Yang, J., Chen, J., Luo, Q., Zhang, Q., and Zhang, H. (2017). Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the renin-angiotensin system. Mol. Med. Rep. 16, 7432–7438. doi:10.3892/mmr.2017.7546
Yang, I., Xu, J., and Zhang, H. (2016). Effects of vitamin D on ACE2 and vitamin D receptor expression in rats with LPS induced acute lung injury. Chin. J. Em. Med. 25, 1284–1289. doi:10.3760/cma.j.issn.1671-0282.2016.12.016
Zdrenghea, M. T., Makrinioti, H., Bagacean, C., Bush, A., Johnston, S. L., and Stanciu, L. A. (2017). Vitamin D modulation of innate immune responses to respiratory viral infections. Rev. Med. Virol. 27. doi:10.1002/rmv.1909
Zhang, Z. R., Leung, W. N., Cheung, H. Y., and Chan, C. W. (2015). Osthole: a review on its bioactivities, pharmacological properties, and potential as alternative medicine. Evid. Based Compl. Alt. Med. 2015, 1–10. doi:10.1155/2015/919616
Zhao, Y., Ran, Z., Jiang, Q., Hu, N., Yu, B., Zhu, L., et al. (2019). Vitamin D alleviates rotavirus infection through a microrna-155-5p mediated regulation of the TBK1/IRF3 signaling pathway in vivo and in vitro. Int. J. Mol. Sci. 20, 3562. doi:10.3390/ijms20143562
Keywords: SARS-CoV-2, COVID 19, respiratory tract infection, vitamin D3, vitamin D3 receptor
Citation: Boulkrane MS, Ilina V, Melchakov R, Fedotova J, Drago F, Gozzo L, Das UN, Abd El-Aty AM and Baranenko D (2020) COVID-19 Disease and Vitamin D: A Mini-Review. Front. Pharmacol. 11:604579. doi: 10.3389/fphar.2020.604579
Received: 09 September 2020; Accepted: 16 November 2020;
Published: 17 December 2020.
Edited by:Cesare Mancuso, Catholic University of the Sacred Heart, Italy
Reviewed by:Peter Bergman, Karolinska Institutet (KI), Sweden
Richard Quinton, Newcastle University, United Kingdom
Copyright © 2020 Boulkrane, Ilina, Melchakov, Fedotova, Drago, Gozzo, Das, Abd El-Aty and Baranenko. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Julia Fedotova, email@example.com